The United States Drug Enforcement Administration (DEA) has recently given an extension on COVID-19–era flexibilities until the end of December 2024, as documented in a temporary rule published on October 6, 2023. This decision upholds a crucial aspect of the COVID-19 response, facilitating healthcare practitioners in their ongoing efforts to administer care remotely via telemedicine.
The extension essentially continues to lift a notable restriction that is invoked by the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. As some legal professionals and healthcare providers might be well aware of, this law typically prohibits practitioners from prescribing controlled substances to patients without first conducting an in-person encounter. However, in light of the challenges posed by the pandemic, these provisions were initially relaxed.
Under the DEA’s extended reprieve, healthcare practitioners can continue to prescribe controlled substances via telemedicine without any prior in-person consultation. This move should significantly aid in ensuring undisturbed delivery of health care services in times where social distancing becomes indispensable. This measure is particularly important for patients with chronic ailments who can’t risk making unnecessary visits to health centers.
However, this noteworthy development also brings with it a demand for caution against potential abuses of online prescription capabilities. Hence, practitioners and corporations alike should remain vigilant and adopt meaningful safeguards against any misuse.
While it remains to be seen how long-term the implications of this reprieve may be, it does open up the possibility of reshaping the accepted norms of patient doctor interaction in certain situations, but only time will tell.
For further information, the cited rule, along with more commentary, is available at
Morgan Lewis – Health Law Scan.